Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ)

Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications. It also provides intermediate products, including rivaroxaban, apixaban, empagliflozin, canagliflozin, ipragliflozin, mirabegron, vibegron, agomelatine, febuxostat, vildagliptin, vonoprazan fumarate, dabigatran etexilate mesylate, azilsartan base and medoxomil potassium, candesartan cilexetil, rimegepant, resmetirom, and opicapone. In addition, the company offers contract manufacturing organization (CMO) services, including production capacity, good manufacturing practice (GMP), regulatory support, research and development for process optimization and scale-up production, and environmental, health, and safety (EHS) management systems. It exports its products to Europe, the United States, Japan, and South Korea. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.